Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07303907) titled 'A Phase 2A Trial of MM402 for Autism Spectrum Disorder' on Dec. 22, 2025.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Mind Medicine, Inc.
Condition:
Autism Spectrum Disorder
ASD
Intervention:
Drug: MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: December 3, 2025
Target Sample Size: 20
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07303...